|
LA JOLLA PHARMACEUTICAL DISCUSSES
PROGRESS AT
J.P. MORGAN H&Q CONFERENCE
SAN FRANCISCO, January 9, 2002 -- La
Jolla Pharmaceutical Company (Nasdaq:
LJPC) today presented an update focused
on an ongoing Phase III clinical trial
for its lupus drug candidate, LJP 394,
and a Phase I/II clinical trial of its
clinical candidate for antibody-mediated
thrombosis, LJP 1082. The Company also
announced that health-related quality
of life results from a previous Phase
II/III clinical trial would be presented
on January 10 at an NIH conference on
lupus.
"With approximately 200 patients
randomized, enrollment continues on
schedule for the Phase III clinical
trial," said Steven B. Engle, Chairman
and Chief Executive Officer. "We
are looking forward to presenting two
papers tomorrow at the National Institutes
of Health and SLE Foundation Conference
on SLE: Targets for New Therapeutics
in Bethesda, Maryland. One of those
presentations will discuss how patients
felt following treatment with LJP 394
in a previous Phase II/III study."
La Jolla Pharmaceutical Company is
a biotechnology company leading the
development of therapeutics for antibody-mediated
autoimmune diseases afflicting several
million patients. The Company is conducting
a Phase III trial of LJP 394 in patients
with lupus kidney disease, a leading
cause of sickness and death in these
patients. The Company is also conducting
a Phase I/II trial of LJP 1082 for the
treatment of antibody-mediated thrombosis,
a condition in which patients suffer
from recurrent stroke, deep-vein thrombosis
and other thrombotic events. The Company's
common stock is traded on The Nasdaq
Stock Market under the symbol LJPC.
Patients interested in the Phase III
lupus trial may call 1-888-30-LUPUS
for information.
Except for historical statements, this
press release contains forward-looking
statements, including, without limitation,
statements regarding the analysis of results
from pre-clinical and clinical studies
as well as La Jolla Pharmaceutical's drug
candidates and drug development plans.
These forward-looking statements involve
risks and uncertainties, and a number
of factors, both foreseen and unforeseen,
could cause actual results to differ materially
from those anticipated. Clinical results
for LJP 394 are derived from a trial that
was terminated prior to completion, and
certain data are incomplete. The Company's
blood test to measure binding affinity
for LJP 394 is experimental and has not
been validated by independent laboratories.
Tolerance, or the specific inactivation
of pathogenic B cells, is a new technology
that has not been proven. The Company's
ability to develop and sell its products
in the future may be affected by the intellectual
property rights of third parties. Future
clinical trials of the Company's drug
candidates may have negative or inconclusive
results. Future clinical trials of the
Company's drug candidates may not support
results of pre-clinical or other prior
trials and clinical trials of LJP 394
for treating lupus or LJP 1082 for treating
antibody-mediated thrombosis may reveal
a potential safety issue requiring the
development of a new candidate. Any delays
in testing of the Company's drug candidates
or termination of development by the Company
would result in delays or lack of government
approval to market the compounds. The
development of drug candidates involves
many risks and uncertainties, including,
without limitation, whether the drug can
provide a meaningful clinical benefit,
and any positive results observed to date
may not be indicative of future results.
La Jolla Pharmaceutical's other potential
drug candidates involve comparable risks.
Interested parties are urged to review
the risks detailed from time to time in
La Jolla Pharmaceutical Company's Securities
and Exchange Commission filings, including
the report on Form 10-K for the year ended
December 31, 2000.
Terms
of Use & Privacy Policy
Copyright © 2008, La Jolla Pharmaceutical Company
|